Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
LASIK
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
=== Experimental techniques === * "plain" LASIK: [[LASEK]], [[Epi-LASIK]], * Wavefront-guided PRK, * advanced [[intraocular lens]]es. * [[Femtosecond laser intrastromal vision correction]]: using all-femtosecond correction, for example, [[Femtosecond Lenticule EXtraction]], [[FLIVC]], or IntraCOR), * Keraflex: a thermobiochemical solution which has received the [[CE marking|CE Mark]] for refractive correction.<ref>{{cite press release|url=http://www.avedro.com/PressReleases/Avedro_CEMark_20April2010.pdf|title=Avedro Receives the European Union's CE Mark for its Vedera Ophthalmic Device|date=20 April 2010|website=Avedro.com|access-date=20 December 2018|archive-date=4 November 2013|archive-url=https://web.archive.org/web/20131104093214/http://www.avedro.com/PressReleases/Avedro_CEMark_20April2010.pdf|url-status=dead}}</ref> and is in European clinical trials for the correction of myopia and keratoconus.<ref>{{cite web |url=http://bmctoday.net/crstodayeurope/2010/05/article.asp?f=industry-interview-aiming-to-change-the-face-of-refractive-surgeryagain |title=CRSTodayEurope.com > May 2010 > Industry interview: Aiming to change the face of refractive surgery—again |website=Bmctoday.net |date=16 April 2010 |access-date=10 December 2011 |archive-date=18 August 2011 |archive-url=https://web.archive.org/web/20110818113109/http://bmctoday.net/crstodayeurope/2010/05/article.asp?f=industry-interview-aiming-to-change-the-face-of-refractive-surgeryagain |url-status=live }}</ref> * Technolas FEMTEC laser: for incisionless IntraCOR ablation for presbyopia,<ref>{{cite web|url=http://www.2010pv.com/dasat/images/3/100373-luis-ruiz-white-paper-0908-final.pdf|title=IntraCOR for presbyopia|website=2010pv.com|access-date=20 December 2018|archive-url=https://web.archive.org/web/20110902212944/http://www.2010pv.com/dasat/images/3/100373-luis-ruiz-white-paper-0908-final.PDF|archive-date=2 September 2011|url-status=dead}}</ref> with trials ongoing for myopia and other conditions.<ref>{{cite web|url=http://www.2010pv.com/dasat/images/4/100544-1st-tpv-alliance-bali-may-2009.pdf|title=IntraCOR for myopia|website=2010pv.com|access-date=20 December 2018|archive-url=https://web.archive.org/web/20110902213023/http://www.2010pv.com/dasat/images/4/100544-1st-tpv-alliance-bali-may-2009.pdf|archive-date=2 September 2011|url-status=dead}}</ref> * LASIK with the IntraLase femtosecond laser: early trials comparing to the LASIK with microkeratomes for the correction of myopia suggest no significant differences in safety or efficacy. However, the femtosecond laser has a potential advantage in predictability, although this finding was not significant.<ref>{{cite journal | vauthors = Chen S, Feng Y, Stojanovic A, Jankov MR, Wang Q | title = IntraLase femtosecond laser vs mechanical microkeratomes in LASIK for myopia: a systematic review and meta-analysis | journal = Journal of Refractive Surgery | volume = 28 | issue = 1 | pages = 15–24 | date = January 2012 | pmid = 22233436 | doi = 10.3928/1081597x-20111228-02 | url = http://www.laservalais.ch/wp-content/uploads/Journal-of-Refractive-Surgery-Janvier-2012.pdf | access-date = 1 November 2015 | archive-date = 7 January 2022 | archive-url = https://web.archive.org/web/20220107065657/https://www.laservalais.ch/wp-content/uploads/Journal-of-Refractive-Surgery-Janvier-2012.pdf | url-status = dead }}</ref>
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)